Pharsight

Sutab generic

Sutab is a gastrointestinal tablet owned by Braintree Labs. It was first authorized for market use on November 10, 2020. The drug's active ingredients include Magnesium Sulfate, Potassium Chloride, and Sodium Sulfate. Sutab holds a total of 4 patents.

When will Sutab generic be available?

The generics for Sutab will likely be available after August 4, 2037. This date is due to the expiry of the drug's last patent on that day, which is titled as 'Solid oral sulfate salt formulations for cleansing a colon and methods of using same'.

Sutab uses

Sutab is primarily used for cleansing the colon in preparation for a colonoscopy. The effectiveness of Sutab is derived from its active ingredients - Magnesium Sulfate, Potassium Chloride, and Sodium Sulfate, which help to clean the colon.

Sutab patent expiration

Sutab holds 4 patents, with the last one expiring on August 4, 2037. The final patent is titled 'Solid oral sulfate salt formulations for cleansing a colon and methods of using same'. Once this patent expires, the process for Sutab generics can begin. Below are the details of the patent:

Sutab dosage

Want to ask something?